Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.42 in the last session, down -7.79% from day before closing price of $1.54. In other words, the price has decreased by -$7.79 from its previous closing price. On the day, 1.91 million shares were traded. ALLO stock price reached its highest trading level at $1.56 during the session, while it also had its lowest trading level at $1.41.
Ratios:
We take a closer look at ALLO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.19 and its Current Ratio is at 8.19. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.24.
Citizens JMP Upgraded its Mkt Perform to Mkt Outperform on March 14, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when Beneski Benjamin Machinas sold 786 shares for $1.22 per share. The transaction valued at 959 led to the insider holds 217,721 shares of the business.
Beneski Benjamin Machinas bought 786 shares of ALLO for $959 on Nov 17 ’25. On Oct 21 ’25, another insider, Parker Geoffrey M., who serves as the CHIEF FINANCIAL OFFICER of the company, sold 36,744 shares for $1.26 each. As a result, the insider received 46,169 and left with 1,276,796 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 319116800 and an Enterprise Value of 152064800.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.50, which has changed by -0.1630435 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 8.70%, while the 200-Day Moving Average is calculated to be 7.33%.
Shares Statistics:
According to the various share statistics, ALLO traded on average about 2.75M shares per day over the past 3-months and 2478490 shares per day over the past 10 days. A total of 223.16M shares are outstanding, with a floating share count of 160.27M. Insiders hold about 28.68% of the company’s shares, while institutions hold 50.55% stake in the company. Shares short for ALLO as of 1764288000 were 18663734 with a Short Ratio of 6.78, compared to 1761868800 on 19094028. Therefore, it implies a Short% of Shares Outstanding of 18663734 and a Short% of Float of 10.0.
Earnings Estimates
The performance of Allogene Therapeutics Inc (ALLO) in the stock market is under the watchful eye of 10.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.18 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.74 and -$1.2 for the fiscal current year, implying an average EPS of -$0.94. EPS for the following year is -$0.91, with 10.0 analysts recommending between -$0.43 and -$1.47.
